Renaissance Capital’s October IPO Market Update The fourth quarter kicked off with 22 IPOs raising a combined $3.8 billion in the busiest month for new issuance in nearly three years, despite an end-of-month slowdown ahead of the US presidential election....read more
Four IPOs each raised at least $75 million this week as the Fall IPO market continued to hum along, while one company postponed its deal. Early childhood education (ECE) provider KinderCare (KLC) priced just below the midpoint of the range...read more
Upstream Bio, a Phase 2 respiratory biotech developing an antibody that targets the TSLP receptor, raised $255 million by offering 15 million shares at $17, the high end of the range of $15 to $17. The company originally planned to offer 12.5 million shares. At...read more
Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $200 million by offering 12.5 million shares at a price range of $15 to...read more
Renaissance Capital’s October IPO Market Update
Renaissance Capital’s October IPO Market Update The fourth quarter kicked off with 22 IPOs raising a combined $3.8 billion in the busiest month for new issuance in nearly three years, despite an end-of-month slowdown ahead of the US presidential election....read more
US IPO Weekly Recap: Active IPO market continues with KinderCare and trio of biotech deals
Four IPOs each raised at least $75 million this week as the Fall IPO market continued to hum along, while one company postponed its deal. Early childhood education (ECE) provider KinderCare (KLC) priced just below the midpoint of the range...read more
Respiratory disorder biotech Upstream Bio prices upsized IPO at $17 high end
Upstream Bio, a Phase 2 respiratory biotech developing an antibody that targets the TSLP receptor, raised $255 million by offering 15 million shares at $17, the high end of the range of $15 to $17. The company originally planned to offer 12.5 million shares. At...read more
Respiratory disorder biotech Upstream Bio sets terms for $200 million IPO
Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $200 million by offering 12.5 million shares at a price range of $15 to...read more